Destiny 2’s enigmatic peddler of rare wares has returned to the Tower, and this week, he’s selling something quite special. From September 20 until the weekly reset on September 24, Bungie has ...

Bungie is doing a lot to encourage people to log back in at the tail end of this episode of Destiny 2 here, and they’ve done ...

Patients with HER2-positive advanced or metastatic breast cancer received trastuzumab deruxtecan every 3 weeks.

The results, published in Nature, strengthen oncologists' understanding of Enhertu's clinical activity as a second-line ...

PFS came in at 61.6% overall, at 62.9% in those with stable brain metastases, and at 59.6% in those with active brain ...

A drug that delivers chemotherapy directly to tumors has shown impressive activity against some of the hardest-to-reach cancer cells: those that have spread to the brain in patients with advanced HER2 ...

A drug that delivers chemotherapy directly to tumors has shown impressive activity against some of the hardest-to-reach cancer cells: those that have spread to the brain in patients with advanced HER2 ...

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

Trastuzumab deruxtecan (T-DXd) was effective in patients with HER2-positive (HER2+) metastatic breast cancer, with no new ...

ENHERTU® Showed Substantial Clinical Activity in Patients with HER2 Positive Metastatic Breast Cancer and Brain Metastases ...

The 12-month progression-free survival (PFS ... recurrence during or within 6 months of therapy completion.2 The full approval was based on findings from the phase 3 DESTINY-Breast03 trial ...

Naomi Dempsey, MD, discussed developments in the HER2-positive breast cancer space, including personalized approaches, less ...